Immix Biopharma NEXICART-2 Achieves 95% Complete Response Rate
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Immix Biopharma announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response - CR -. The NEXICART-2 CR rate is now 95% - 19 out of 20 patients -. All CRs were reached within 1 year of follow-up post-dosing. No relapses have been observed as of today for patients who have reached CR. All subsequently enrolled patients for whom MRD results are available are MRD-negative at one month. The next NEXICART-2 update is expected late September. These results support the company's plan to initiate a multi-center, randomized Phase 3 trial in newly diagnosed AL Amyloidosis patients. AL amyloidosis is a devastating disease where the immune system continuously produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. NXC-201 has been awarded Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy by the FDA, and Orphan Drug Designation by the FDA and in the EU by the EMA.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMX
Wall Street analysts forecast IMMX stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.940
Low
8.00
Averages
8.00
High
8.00
Current: 8.940
Low
8.00
Averages
8.00
High
8.00
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immix Biopharma Prices $150 Million Underwritten Offering
- Offering Size: Immix Biopharma announced the pricing of 16,778,524 shares at $8.94 each, aiming for gross proceeds of $150 million, which will be allocated to the development of NXC-201 and operational funding, thereby enhancing the company's financial stability and R&D capabilities.
- Use of Proceeds: The net proceeds from this offering are intended to support the development of NXC-201, working capital, and general corporate purposes, with expectations to meet operational needs into mid-2028, ensuring the company's sustained competitiveness in the AL Amyloidosis sector.
- Underwriting Team: Morgan Stanley serves as the lead book-running manager, with BofA Securities participating as a book-running manager, and LifeSci Capital, Mizuho, and Needham & Company acting as co-lead managers, reflecting strong market confidence in Immix and its influence in the biopharmaceutical field.
- Regulatory Compliance: The offering is conducted under a registration statement with the U.S. Securities and Exchange Commission, ensuring compliance and providing transparency for investors, which further enhances trust in the company's future development.
See More
Immix Biopharma Prices Public Offering at $8.94 per Share
- Offering Pricing: Immix Biopharma has successfully priced its offering of 16,778,524 shares at $8.94 per share, with gross proceeds expected to reach $150 million after deducting underwriting discounts and other expenses, significantly enhancing the company's financial strength for future growth.
- Use of Proceeds: The funds raised will support the development of the CAR-T cell therapy NXC-201, as well as working capital and other general corporate purposes, ensuring the company's operational sustainability over the next few years.
- Expected Closing Date: The offering is anticipated to close on or about May 22, 2026, subject to customary closing conditions, providing investors with a clear timeline for the expected influx of capital.
- Stock Performance: Immix shares closed at $8.94 on Wednesday and rose 10% premarket on Thursday to $9.93, reflecting optimistic market sentiment towards the company's future developments, which may attract more investor interest.
See More
Immix Biopharma Achieves 95% CR in NXC-201 Trial
- Clinical Trial Success: Immix Biopharma has achieved a 95% complete response rate in the NEXICART-2 trial, indicating significant efficacy of NXC-201 in treating relapsed/refractory AL Amyloidosis, which could transform treatment paradigms.
- Patient Response Data: Among the first 20 patients, 19 achieved complete response, with all four MRD-negative patients converting to complete response, showcasing the robust therapeutic potential of NXC-201.
- Market Outlook: According to Grand View Research, the AL Amyloidosis market is projected to grow from $3.6 billion in 2017 to $6 billion by 2025, highlighting substantial commercial opportunities for Immix Biopharma in this sector.
- Future Plans: The company plans to share further updates on NEXICART-2 in September 2026 and intends to initiate a multi-center randomized Phase 3 trial for newly diagnosed AL Amyloidosis patients, aiming to further validate the efficacy of NXC-201.
See More
Immix Biopharma Reports Promising NXC-201 Trial Data in AL Amyloidosis
- Clinical Trial Success: Immix Biopharma's mid-stage trial for NXC-201 in AL amyloidosis shows a remarkable 95% complete response rate, with 19 out of 20 patients achieving CR, highlighting the treatment's potential in addressing rare diseases.
- No Relapse Record: Over a one-year follow-up period, all patients who achieved complete responses experienced no relapses, which not only enhances the treatment's safety profile but also solidifies the foundation for future clinical trials, boosting investor confidence.
- Future Trial Plans: The company intends to share the latest updates from the NEXICART-2 trial by late September and plans to initiate a Phase 3 trial for newly diagnosed AL amyloidosis patients, demonstrating its ongoing commitment to research and development in this area.
- Funding Initiative: Immix Biopharma is conducting an underwritten equity offering at $8.94 per share, aiming to raise $150 million, which will provide essential funding for its upcoming clinical trials and research efforts, further propelling the company's growth.
See More
Immix Biopharma Initiated with Overweight Rating by Morgan Stanley
- Rating Upgrade: Morgan Stanley initiated coverage on Immix Biopharma (IMMX) with an Overweight rating and a $20 price target, reflecting the analyst's strong optimism about its lead candidate NXC-201, which is expected to drive stock price appreciation.
- Clinical Trial Progress: NXC-201 is currently undergoing the mid-stage NEXICART-2 trial for relapsed/refractory AL amyloidosis, a rare disease with no approved therapies, highlighting the drug's market potential and clinical need.
- FDA Approval Outlook: With Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA, NXC-201 is poised for potential accelerated approval in the U.S., enhancing its market competitiveness and commercial value.
- Revenue Projections: The analyst projects approximately $802 million in peak risk-adjusted revenue for NXC-201 in R/R AL amyloidosis, with final pivotal data expected in H2 2026, followed by an FDA marketing application and a projected product launch in H1 2027.
See More
Latest Rating Changes on Wall Street
- Tesla Neutral Rating: Goldman Sachs maintains a neutral stance on Tesla, expressing caution regarding its semiconductor ventures, noting a mixed track record in semiconductor engineering, while suggesting potential applications for inference chips in data centers and distributed computing remain to be seen.
- Upgrade Based on Iran War: Wells Fargo upgrades Kinetik, ONEOK, and Enterprise Products Partners from equal weight to overweight, anticipating that the Iran war will create a structural shift in global energy markets, boosting demand for U.S. energy, particularly in Permian gas and NGL supply.
- ESCO Technologies Buy Initiation: Deutsche Bank initiates coverage on ESCO Technologies with a Buy rating and a $350 target price, highlighting its potential for “defensive growth at a discount” in the aerospace and defense sectors, indicating strong confidence in the company's future.
- Arm Rating Upgrade: Wolfe upgrades Arm from market perform to outperform, citing the company's recent in-house chip launch and significantly increased earnings forecasts for FY28 and FY31, setting a target price of $166, reflecting optimism about its new business model.
See More
Immix Biopharma Prices $150 Million Underwritten Offering
- Offering Size: Immix Biopharma announced the pricing of 16,778,524 shares at $8.94 each, aiming for gross proceeds of $150 million, which will be allocated to the development of NXC-201 and operational funding, thereby enhancing the company's financial stability and R&D capabilities.
- Use of Proceeds: The net proceeds from this offering are intended to support the development of NXC-201, working capital, and general corporate purposes, with expectations to meet operational needs into mid-2028, ensuring the company's sustained competitiveness in the AL Amyloidosis sector.
- Underwriting Team: Morgan Stanley serves as the lead book-running manager, with BofA Securities participating as a book-running manager, and LifeSci Capital, Mizuho, and Needham & Company acting as co-lead managers, reflecting strong market confidence in Immix and its influence in the biopharmaceutical field.
- Regulatory Compliance: The offering is conducted under a registration statement with the U.S. Securities and Exchange Commission, ensuring compliance and providing transparency for investors, which further enhances trust in the company's future development.
See More
Immix Biopharma Prices Public Offering at $8.94 per Share
- Offering Pricing: Immix Biopharma has successfully priced its offering of 16,778,524 shares at $8.94 per share, with gross proceeds expected to reach $150 million after deducting underwriting discounts and other expenses, significantly enhancing the company's financial strength for future growth.
- Use of Proceeds: The funds raised will support the development of the CAR-T cell therapy NXC-201, as well as working capital and other general corporate purposes, ensuring the company's operational sustainability over the next few years.
- Expected Closing Date: The offering is anticipated to close on or about May 22, 2026, subject to customary closing conditions, providing investors with a clear timeline for the expected influx of capital.
- Stock Performance: Immix shares closed at $8.94 on Wednesday and rose 10% premarket on Thursday to $9.93, reflecting optimistic market sentiment towards the company's future developments, which may attract more investor interest.
See More
Immix Biopharma Achieves 95% CR in NXC-201 Trial
- Clinical Trial Success: Immix Biopharma has achieved a 95% complete response rate in the NEXICART-2 trial, indicating significant efficacy of NXC-201 in treating relapsed/refractory AL Amyloidosis, which could transform treatment paradigms.
- Patient Response Data: Among the first 20 patients, 19 achieved complete response, with all four MRD-negative patients converting to complete response, showcasing the robust therapeutic potential of NXC-201.
- Market Outlook: According to Grand View Research, the AL Amyloidosis market is projected to grow from $3.6 billion in 2017 to $6 billion by 2025, highlighting substantial commercial opportunities for Immix Biopharma in this sector.
- Future Plans: The company plans to share further updates on NEXICART-2 in September 2026 and intends to initiate a multi-center randomized Phase 3 trial for newly diagnosed AL Amyloidosis patients, aiming to further validate the efficacy of NXC-201.
See More
Immix Biopharma Reports Promising NXC-201 Trial Data in AL Amyloidosis
- Clinical Trial Success: Immix Biopharma's mid-stage trial for NXC-201 in AL amyloidosis shows a remarkable 95% complete response rate, with 19 out of 20 patients achieving CR, highlighting the treatment's potential in addressing rare diseases.
- No Relapse Record: Over a one-year follow-up period, all patients who achieved complete responses experienced no relapses, which not only enhances the treatment's safety profile but also solidifies the foundation for future clinical trials, boosting investor confidence.
- Future Trial Plans: The company intends to share the latest updates from the NEXICART-2 trial by late September and plans to initiate a Phase 3 trial for newly diagnosed AL amyloidosis patients, demonstrating its ongoing commitment to research and development in this area.
- Funding Initiative: Immix Biopharma is conducting an underwritten equity offering at $8.94 per share, aiming to raise $150 million, which will provide essential funding for its upcoming clinical trials and research efforts, further propelling the company's growth.
See More
Immix Biopharma Initiated with Overweight Rating by Morgan Stanley
- Rating Upgrade: Morgan Stanley initiated coverage on Immix Biopharma (IMMX) with an Overweight rating and a $20 price target, reflecting the analyst's strong optimism about its lead candidate NXC-201, which is expected to drive stock price appreciation.
- Clinical Trial Progress: NXC-201 is currently undergoing the mid-stage NEXICART-2 trial for relapsed/refractory AL amyloidosis, a rare disease with no approved therapies, highlighting the drug's market potential and clinical need.
- FDA Approval Outlook: With Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the FDA, NXC-201 is poised for potential accelerated approval in the U.S., enhancing its market competitiveness and commercial value.
- Revenue Projections: The analyst projects approximately $802 million in peak risk-adjusted revenue for NXC-201 in R/R AL amyloidosis, with final pivotal data expected in H2 2026, followed by an FDA marketing application and a projected product launch in H1 2027.
See More
Latest Rating Changes on Wall Street
- Tesla Neutral Rating: Goldman Sachs maintains a neutral stance on Tesla, expressing caution regarding its semiconductor ventures, noting a mixed track record in semiconductor engineering, while suggesting potential applications for inference chips in data centers and distributed computing remain to be seen.
- Upgrade Based on Iran War: Wells Fargo upgrades Kinetik, ONEOK, and Enterprise Products Partners from equal weight to overweight, anticipating that the Iran war will create a structural shift in global energy markets, boosting demand for U.S. energy, particularly in Permian gas and NGL supply.
- ESCO Technologies Buy Initiation: Deutsche Bank initiates coverage on ESCO Technologies with a Buy rating and a $350 target price, highlighting its potential for “defensive growth at a discount” in the aerospace and defense sectors, indicating strong confidence in the company's future.
- Arm Rating Upgrade: Wolfe upgrades Arm from market perform to outperform, citing the company's recent in-house chip launch and significantly increased earnings forecasts for FY28 and FY31, setting a target price of $166, reflecting optimism about its new business model.
See More
